International Biotechnology Trust plc - IBT

Investing in biotechnology for a healthier future

Access the fast-growing biotechnology sector through an actively managed, diversified investment trust

Targeting high growth, International Biotechnology Trust plc (IBT) backs innovative companies addressing high unmet medical needs and offers investors the opportunity for financial returns.

Behind the trust - read our philosophy article >

Seeking the best in biotech

International Biotechnology Trust invests in around 100 of the most innovative, high quality quoted and unquoted companies across the entire spectrum of the biotech and other life sciences sectors.

A keen focus on risk management

An acute understanding of valuation and the biotechnology investment cycle informs the managers’ top down overlay and they take prudent steps to reduce individual company risk ahead of binary events. This has contributed to their outperformance against the index and their peers.

Income generating

A dividend of 4% of closing net asset value, paid biannually, offers investors a highly differentiated and reliable source of income.

IBT Manager Update

On Tuesday 28 January 2025, Portfolio Managers Ailsa Craig and Marek Poszepczynski gave insight on their 2025 market outlook

Portfolio & Performance Hub

In the media

Slide 1 of 15
Johnson and Johnson’s acquisition of Intra-Cellular Therapies
Kepler: IBT’s managers are positioned for the sector’s recovery to continue
Kepler podcast: Trust Issues - investing in biotech with IBT
Investor Download Podcast: Why now might be a good time to invest in biotech
Shares: Weight-loss drug stock rally: is it over or simply catching its breath?
City A.M: Meet the Fund Manager with Ailsa Craig
Kepler: Why the biotech sector is bouncing back to rude health
QuotedData: Time to inject some healthcare into your portfolio?
Interactive Investor: Funds and trusts four pros are buying and selling: Q3 2024
Kepler: IBT gains 3% from M&A deal
Morningstar: Interview with Ailsa Craig
Kepler Article: 'Many Happy Returns'
The acquisition of EyeBio by Merck
AJ Bell/ Shares: Investor Presentation May 2024
Interactive Investor: Is this stock market theme a big opportunity or a bubble?

Investment Manager's Blog

Slide 1 of 0

Documents

Slide 1 of 9